AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 282: H38-H48, 2002. First published September 27, 2001; doi:10.1152/ajpheart.00536.2001
0363-6135/02 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/1/H38    most recent
00536.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by duBell, W. H.
Right arrow Articles by Rogers, T. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by duBell, W. H.
Right arrow Articles by Rogers, T. B.
Vol. 282, Issue 1, H38-H48, January 2002

Effects of PP1/PP2A inhibitor calyculin A on the E-C coupling cascade in murine ventricular myocytes

William H. duBell1,*, Marisa S. Gigena1,*, Silvia Guatimosim2,3, Xilin Long1, W. J. Lederer2,3, and Terry B. Rogers1

1 Department of Biochemistry and Molecular Biology, and 2 Department of Physiology, University of Maryland School of Medicine, and 3 Medical Biotechnology Center, University of Maryland Biotechnology Institute, University of Maryland School of Medicine, Baltimore, Maryland 21201


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Calyculin A was used to examine the importance of phosphatases in the modulation of cardiac contractile magnitude in the absence of any neural or humoral stimulation. Protein phosphatase (PP)1 and PP2A activity, twitch contractions, intracellular Ca2+ concentration ([Ca2+]i) transients, action potentials, membrane currents, and myofilament Ca2+ sensitivity were measured in isolated mouse ventricular myocytes. Calyculin A (125 nM) inhibited PP1 and PP2A by 50% and 85%, respectively, whereas it doubled the twitch magnitude and increased twitch duration by 50% in field-stimulated cells. Calyculin A-evoked increases in L-type Ca2+ current (70%) and the resulting [Ca2+]i transient (83%) explain the positive inotropic response. However, increases in twitch and action potential durations did not result from increased myofilament Ca2+ sensitivity or K+ current inhibition, respectively. Comparison of the effects of calyculin A and isoproterenol on [Ca2+]i transients and twitch contractions revealed that calyculin A had a much smaller lusitropic effect than the beta -agonist, indicating that calyculin A did not significantly increase sarcoplasmic reticulum Ca2+ reuptake. Thus while cardiac contractile magnitude is controlled by a steady-state kinase/phosphatase balance, this regulation is not equally operative at all of the steps in the excitation-contraction coupling pathway and may in fact be most important to the regulation of the L-type Ca2+ channel.

calcium current; calcium transient; phosphorylation; indo 1; fluo 3


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

INTRACELLULAR SIGNALING SPECIFICITY is determined in part by targeting of signaling cascades to discrete subcellular locations. In heart cells, A-kinase anchoring proteins are important in defining the signaling specificity of protein kinase A (PKA) (11) and may be essential for L-type Ca2+ channel regulation (22). There is also evidence for protein kinase C (PKC)-epsilon targeting in heart cells (37, 45). Yet much less is known of the phosphatases that oppose the action of such kinases. Biochemical studies (34, 47) suggest that protein phosphatase (PP)1 acts as a phospholamban phosphatase regulating sarcoplasmic reticulum (SR) function, whereas PP2A may regulate myofilament function as a "troponin I phosphatase" (38). Furthermore, immunoprecipitation studies (10, 35, 36) have shown that PP2A is directly associated with the cardiac ryanodine receptor and the alpha 1-subunit of the L-type Ca2+ channel. The fact that these enzymes can be precisely targeted suggests they are important signaling elements. However, the physiological roles of these signaling enzymes in cardiac cells remain to be defined.

Phosphatase inhibitors can reveal the presence of a dynamic balance between protein phosphorylation and dephosphorylation. PP1/PP2A inhibitors, such as okadaic acid and calyculin A, have been shown to stimulate L-type Ca2+ channel function in the absence of humoral stimulation (27, 28, 40, 41). Addition of exogenous phosphatases can also reveal such a dynamic balance. A previous study (13) from this laboratory demonstrated that intracellular dialysis of rat ventricular myocytes with either PP1 or PP2A decreased the magnitude of the cytosolic intracellular Ca2+ concentration ([Ca2+]i) transient in the steady state without decreasing SR Ca2+ load. These studies reveal the importance of phosphatases in local control in the heart. In fact, because PP1/PP2A comprise the majority of serine-threonine phosphatase activity within cells, it might be expected that these enzymes are important regulators of many components of the excitation-contraction (E-C) coupling cascade, including the membrane currents involved in excitation, the proteins involved in uptake and release of Ca2+, and the myofilaments that transduce the Ca2+ signal into mechanical activity.

In the present study, calyculin A, a potent inhibitor of PP1 and PP2A (30), was used to characterize which components of the E-C coupling cascade are regulated by such a kinase/phosphatase balance in mouse ventricular myocytes. The murine heart model was chosen so that the results could be used to design future studies to exploit transgenic animal models. The goals of this study were as follows: 1) to accurately and precisely measure the activity of PP1 and PP2A and their inhibition by calyculin A in mouse ventricular myocytes, 2) to define the biological role of calyculin A-sensitive PP1 and PP2A in maintaining cardiac contractility in the absence of any receptor-activated signaling, and 3) to identify the specific components of the cardiac E-C coupling cascade whose activities are controlled in this manner. An important conclusion from these studies is that PP1 and/or PP2A, in concert with as-yet-unidentified protein kinase(s), control the level from which receptor-activated signaling pathways regulate contractility. This function is carried out primarily through control of L-type Ca2+ current (ICa) rather than by acting at all of the steps of the E-C coupling cascade.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Cardiac myocyte preparation. Hearts were removed from adult male CD-1 mice anesthetized with 30 mg/kg ip of pentobarbital sodium (Abbott Laboratories). The aorta was cannulated for Langendorff perfusion, and ventricular myocytes were isolated by a standard enzymatic technique exactly as described previously (14). The cells were maintained at room temperature in HEPES-buffered DMEM with 10% fetal calf serum. All experiments were carried out within 8 h of cell isolation.

Incubation with calyculin A. Cells were preincubated with varying concentrations (100 nM-1 µM) of calyculin A (Alexis Biochemicals) from a 1 mM stock in DMSO. Control cells were preincubated with equal volumes of DMSO alone. Calyculin A was present only during the preincubation period. After 15-30 min of preincubation, the cells were used for either biochemical or functional experiments. A small number of experiments (summarized in Fig. 7) were performed in which cells were exposed to calyculin A and staurosporine during voltage-clamp experiments. Voltage-clamp recordings were made in control, in the presence of calyculin A (100 nM), or with the serine-threonine protein kinase inhibitor staurosporine (300 nM) and then in the presence of both calyculin A and staurosporine. Both agents were added from stock solutions in DMSO, and an equal concentration of DMSO (0.04%) was present in all of the experimental solutions.

Phosphatase assays. Suspensions of myocytes were rapidly washed with 0.9% NaCl and then homogenized in lysis buffer consisting of HEPES-NaOH (20 mM, pH 7.5), NaCl (100 mM), protease inhibitor cocktail (1:400, Sigma P8340), and 0.02% beta -mercaptoethanol. The cell extracts were centrifuged at 178,000 g for 10 min at 4°C. Protein concentration in the supernatant was determined spectrophotometrically with Bradford's reagent (Bio-Rad) using BSA as the standard.

PP1 activity was measured in these crude extracts with [32P]phosphorylase a as a pseudosubstrate using a technique modified from Cohen et al. (9). The activity was measured in the presence of 10 nM okadaic acid to block PP2A activity (6) in a 60-µl reaction volume containing 50 mM Tris · HCl (pH 7.6), 0.1 mM EDTA, 0.7 mg/ml BSA, 50 mM NaCl, 30 mM beta -mercaptoethanol, 3.3 mM caffeine, 0.25 mg/ml [32P]phosphorylase a, and 350 ng supernatant protein. After a 15-min incubation period at 30°C, the reaction was stopped by adding 180 µl of 20% (vol/vol) trichloroacetic acid (TCA). After an additional 10 min on ice, the mixture was centrifuged at 12,000 g for 3 min at 4°C. The supernatant was collected, and the amount of 32Pi released during the reaction was quantified by liquid scintillation counting. PP1 specific activity, expressed as nanomoles of 32Pi released per minute per milligram of protein, was defined as the activity measured in the presence of 10 nM okadaic acid minus the residual activity in the presence of 500 nM okadaic acid. The specificity of the assay is depicted in Fig. 1A.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Specificity of [32P]phosphorylase a and RRATpVA peptide assays. Cytosolic fractions from homogenized myocytes were assayed for phosphatase activity with [32P]phosphorylase a (A) or RRATpVA (B). A: phosphatase activity towards [32P]phosphorylase a in the absence of any inhibitors (total activity), in the presence of 10 nM okadaic acid [OA; inhibits protein phosphatase (PP)2A], 1 µM inhibitor-2 (specific PP1 inhibitor), 500 nM OA (inhibits PP2A and PP1), and inhibitor-2 plus 10 nM OA. Note that both 500 nM OA and the combination of 1 µM inhibitor-2 and OA, which should each completely inhibit PP1 and PP2A, have the same effect on 32Pi release. B: total phosphatase activity toward RRATpVA in the presence and absence of 10 nM OA. Note that 10 nM OA, which is without effect on PP1 (6), inhibits >80% of the 32Pi release from RRATpVA.

A different assay was developed to measure PP2A activity in these crude extracts. The rationale for using the two separate assays is shown in Fig. 1. The fraction of the total "phosphorylase a phosphatase" activity in murine cardiac cell extracts attributable to PP1 and PP2A can be determined from the activity inhibited by 10 nM okadaic acid (PP2A, see PP2A bracket in Fig. 1A) and the activity blocked by a specific PP1 inhibitor, inhibitor-2 (1 µM, see PP1 bracket in Fig. 1A). Whereas ~60% of the total activity measured using phosphorylase a can be directly attributed to PP1, PP2A activity comprises only 18% of the total under these conditions (Fig. 1A). Accordingly, an independent and more precise assay was developed that uses a 32P-labeled synthetic peptide, RRATpVA, which should be selective for PP2A (44). RRATpVA was prepared by reacting 30 µCi [gamma -32P]ATP with 40 µg unphosphorylated peptide in a 200-µl total volume containing 10 units of the PKA catalytic subunit (Sigma), 70 mM MES, and 15 mM MgCl2. After 1 h of incubation at 30°C, 10 more units of PKA were added, and the reaction was continued for another hour. The reaction was stopped by adding 200 µl of 30% acetic acid. The 32P-labeled phosphopeptide was purified by applying the reaction volume onto a preequilibrated solid-phase extraction column (Sep-Pak C18 cartridges, Waters). The column was then washed with 0.1% trifluoroacetic acid (TFA) until the radioactivity of the effluent was <1,000 counts · min-1 · µl-1. The phosphopeptide was eluted as one radioactive peak with successive additions of 500 µl of 30% acetonitrile in 0.1% TFA. The effluents containing the highest concentration of 32P-labeled RRATpVA were combined, aliquoted, and frozen for use.

To assay PP2A activity, cell extracts (0.4 µg of protein) were incubated with 20,000 counts/min of 32P-labeled RRATpVA in reaction buffer containing 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, and 0.02% beta -mercaptoethanol in the presence or absence of 10 nM okadaic acid. After 15 min of incubation at 30°C, the reaction was terminated by adding 500 µl of 100 mM K2PO4 in 5% TCA. The 32P-labeled peptide and 32Pi released were separated by applying the total reaction volume (550 µl) onto an ion exchange column (1 ml Dowex 50WX8 200-400 mesh, H form). The 32Pi was eluted from the columns in 500 µl H2O and quantified by liquid scintillation counting. It is important to note that the assay was linear with respect to both protein and time under these conditions. PP2A activity, expressed as femtomoles of 32Pi released per minute per milligram of protein, was defined as the component of total phosphatase activity that was inhibited by 10 nM okadaic acid (Fig. 1B). The specificity of the assay for PP2A is clearly demonstrated in Fig. 1B. With the use of RRATpVA, ~85% of the total activity was sensitive to 10 nM okadaic acid, a concentration that is without effect on PP1. Thus the use of these two assays in parallel allows the precise measurement of PP1 and PP2A activity in crude cardiac cell extracts.

Field stimulation and edge detection. These experiments were conducted at room temperature on a Nikon Diaphot inverted microscope. Cells were superfused with extracellular buffer consisting of 100 mM NaCl, 5 mM KCl, 25 mM NaHCO3, 25 mM HEPES, 1.0 mM Na2HPO4, 1.0 mM MgSO4, 10 mM D-glucose, and 1.8 mM CaCl2 at pH 7.4 (NaOH). Cells were field stimulated (Grass S48) at 1 Hz with 5-ms pulses with a magnitude of ×1.5 threshold through platinum wires mounted in the bottom of the experimental chamber. Twitch contractions were recorded using a video-based edge detector (Crescent Electronics), digitized at 500 Hz (PP-50 Lab Patch Panel, Warner Instrument and Axotape, Axon Instruments), and analyzed off-line. Contractions were normalized to the resting cell length.

Field stimulation and [Ca2+]i transients. Cells were loaded with fluo 3 by incubating a 2-ml cell suspension with 30 µl of 0.5 µg/µl fluo 3-AM stock in 20% (wt/vol) pluronic F-127 in DMSO. The final concentration of fluo 3-AM was 6.6 µM. Fluo 3-loaded cells were field stimulated (1 Hz) as described in Field stimulation and edge detection on a Bio-Rad MRC 600 laser scanning confocal microscope equipped with a Zeiss Neofluor ×63 oil immersion lens (numerical aperture = 1.25). Images were obtained in line-scan mode, processed, and analyzed using COMOS (Bio-Rad) and IDL5.2 (Research Systems) software. To measure [Ca2+]i transients, the fluorescence images were normalized by dividing the fluorescence intensity of each pixel (F) by the average resting fluorescence intensity (F0) to generate an F/F0 image. Cell length during each line scan was measured by determining the portion of the scan line that exhibited fluo 3 fluorescence.

Action potential measurements. Action potential measurements were made at 35°C using low-resistance patch type microelectrodes and an Axopatch 200A with a CV202A head stage (Axon Instruments). The filling solution consisted of the following: 110 mM potassium aspartate, 20 mM KCl, 10 mM NaCl, 4 mM MgATP, and 10 mM HEPES at pH 7.3 (with KOH). The extracellular solution was the same as that used for the field stimulation experiments. The cells were stimulated (1 Hz) by applying a brief (2-5 ms) hyperpolarizing current clamp pulse. After release of this pulse, the cells reached threshold and generated an action potential.

Voltage-clamp experiments. These experiments were conducted at 35°C on a Nikon Diaphot 200 inverted microscope that was modified, as previously described (13), for the simultaneous measurement of membrane current and [Ca2+]i. The voltage-clamp amplifier was an Axopatch 200A with a CV202A head stage. Whole cell voltage clamp was carried out using low-resistance (<2 MOmega ) patch type microelectrodes. Cells were placed in the experimental chamber and superfused with a solution containing 140 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM MgCl2, 0.33 mM NaH2PO4, and 10 mM D-glucose at pH 7.4 (with NaOH). The pipette filling solution used for simultaneous measurements of ICa and the cytosolic Ca2+ ([Ca2+]i) transient consisted of 130 mM CsCl, 10 mM HEPES, 20 mM TEA chloride, 1.0 mM MgCl2, 5.0 mM MgATP, and 25 µM K5indo 1 at pH 7.3 (with CsOH). After whole cell access was attained, a modified superfusate was used, which included CsCl (substituted for KCl), 5 mM 4- aminopyridine, 10 mM TEA chloride to block K+ channels, and 10 µM TTX to block Na+ channels. Extracellular Ca2+ concentration ([Ca2+]o) was 1.8 mM (CaCl2). ICa was recorded from a holding potential of -40 mV. [Ca2+]i was calibrated using a previously described in vitro technique (13). K+ currents were recorded using KCl-based intra- and extracellular solutions as described previously (14). [Ca2+]o was 0.1 mM, and nifedipine (0.5 µM) and TTX (10 µM) were included to block ICa and Na+ current, respectively.

Voltage-clamp recordings were low-pass filtered by the amplifier at 2 kHz, digitized at 5 kHz (Digidata 1200, Axon Instruments), and stored on a computer for subsequent analysis. Fluorescence was simultaneously digitized at the same rate after low-pass filtering at 100 Hz (Frequency Devices). All currents were normalized to cell capacitance and are reported as current densities (in pA/pF). Cell capacitance was calculated by integrating the uncompensated capacity transients elicited by 10-ms hyperpolarizing pulses from -70 to -80 mV.

Myofilament Ca2+ sensitivity. These experiments were conducted on the same apparatus used to measure field-stimulated twitch contractions. EGTA-buffered solutions consisting of (in mM) 7 EGTA, 25 imidazole, 1 MgCl2, 80 KCl, and 4 MgATP at pH 7.0 (with KOH) (29) were prepared at the following Ca2+ concentrations (in nM): 1, 100, 200, 300, 400, and 500. The amount of CaCl2 required to achieve each Ca2+ concentration was calculated using a computer program that can account for the binding of Ca2+ and other cations to EGTA and the other constituents of the solution (16). CaCl2 was added from a 250 mM stock prepared using a calcium standard solution (EM Science). An aliquot of cells was placed in the experimental chamber and superfused with solution containing 1 nM Ca2+. After several minutes of superfusion, cells were exposed for 1 min to a solution containing 1 nM Ca2+ and 10 µM digitonin (Sigma). Preliminary experiments showed that this was sufficient to permeabilize the myocytes. This was followed in succession by 5 min of superfusion with digitonin-free solutions described above (1-500 nM Ca2+). During the last minute of exposure in each concentration, when cell length had reached a new steady state, a measurement was taken. Myofilament Ca2+ sensitivity was assessed by normalizing cell length at each Ca2+ concentration to that at 1 nM Ca2+ and plotting the resulting average shortening values versus Ca2+ concentration.

Statistics. The experimental values are expressed as means ± SE, with statistical significance (P < 0.05) assessed using Student's paired t-test.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

A recent report (13) from this laboratory demonstrated that increasing the activity of PP1 or PP2A in cardiac cells had selective effects on elements of the E-C coupling cascade. In the present study, we used PP1 and PP2A inhibitors to further explore the selectivity and targeting of phosphatase action. Although there are several PP1/PP2A inhibitors that are frequently used in biochemical studies, it is essential to confirm their efficacy and specificity in intact cells (17). Accordingly, experiments were designed to assess the ability of phosphatase inhibitors to act on these enzymes in intact murine ventricular myocytes, as described in Fig. 1 and METHODS. Initial experiments with okadaic acid revealed that even long incubations (2 h) resulted in only minimal inhibition of PP1 or PP2A (data not shown). This is likely due to its low membrane permeability (17). The effects of calyculin A were quite different, as shown in Fig. 2. A 15-min incubation with 125 nM calyculin A resulted in inhibition of PP1 activity by 52%, whereas 1 µM calyculin A further reduced the activity to 34% of control. Calyculin A proved to be a more potent inhibitor of PP2A under these conditions, reducing the activity to zero at a concentration of 1 µM. Accordingly, calyculin A was used in all of the studies described below.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of cytosolic PP1 and PP2A by incubation of isolated mouse ventricular myocytes with calyculin A. Cytosolic fractions from suspensions of homogenized myocytes were assayed for phosphatase activity with a 32P-labeled substrate specific for either PP1 (A) or PP2A (B) (see Fig. 1 and METHODS). A: PP1 activity after preincubation with DMSO alone (control, n = 4), 125 nM calyculin A (n = 3), or 1 µM calyculin A (n = 3). B: the same as for PP2A: control (n = 5), 125 nM calyculin A (n = 4), and 1 µM calyculin A (n = 5).

On the basis of these results, we examined the effects of calyculin A on the twitch contractions of single isolated mouse ventricular myocytes. In fact, calyculin A had a profound effect on the field-stimulated twitch contraction, as shown in Fig. 3. Calyculin A (125 nM) increased the average magnitude of contraction by 106%, from 8.6 ± 0.6% (n = 26) to 17.7 ± 0.7% (n = 17) of resting length. The duration of the contraction, measured as the time from 50% contraction to 50% relaxation, was also greater, increasing by 47% from 109 ± 3 to 159 ± 7 ms. These effects were maximal, because there was no additional effect of 1 µM calyculin A (n = 18) on twitch magnitude (17.5 ± 0.9% of resting length) or duration (156 ± 4 ms). Interestingly, although the twitch was greatly prolonged in calyculin A, there was no effect on the kinetics of twitch relaxation. The average time constant (tau ) of relaxation was 39 ± 1 ms in control and 43 ± 3 ms in cells preincubated with calyculin A. The lack of effect of calyculin A on relaxation kinetics is apparent in the normalized contractions shown in Fig. 3B.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of preincubation in calyculin A on cell shortening in field-stimulated mouse ventricular myocytes. A: superimposed twitch contractions from a control cell and a cell preincubated with 1 µM calyculin A. Each tracing is the average of 10 consecutive steady-state twitch contractions. Cell length during the contraction was normalized to resting cell length (RL) and is plotted as %RL vs. time. B: same contractions normalized between resting length and length at peak contraction.

Increased myofilament Ca2+ sensitivity could explain the effects of calyculin A on the twitch contraction. Thus chemically skinned isolated mouse ventricular myocytes were used to measure possible increases in myofilament Ca2+ sensitivity. After preincubation in DMSO alone or in calyculin A, cells were permeabilized on the microscope stage with 10 µM digitonin. Cell length was measured after equilibration with solutions containing free Ca2+ concentrations ranging from 1 to 500 nM. The results are summarized in Fig. 4. Control cells exhibited no change in length as the Ca2+ concentration in the superfusate was increased from 1 to 100 nM. However, there was a significant decrease in length, to 99.2 ± 0.3% of resting length (P = 0.009), as the Ca2+ concentration was increased from 100 to 200 nM. There were additional incremental decreases in cell length (P < 0.05) as [Ca2+]o was increased to a concentration of 500 nM. The mean cell length at 500 nM Ca2+ was 91.9 ± 1.1% of resting length. Above 500 nM Ca2+, most cells hypercontracted, presumably because of the absence of a mechanical load. To validate that increases in myofilament Ca2+ sensitivity could be detected, the Ca2+ dependence of cell length was measured in the presence of caffeine (15, 49). As expected, caffeine significantly increased the extent of shortening at 200 nM Ca2+ (P = 0.012), and the effect persisted as [Ca2+]o was increased (P < 0.05). The effects of the PKA activator 8-bromo-cAMP were also examined (25, 42). Cells preincubated with 20 µM 8-bromo-cAMP exhibited less shortening than control cells at all concentrations of Ca2+. The effect reached statistical significance at 500 nM Ca2+, with shortening to 95.8 ± 0.9% of resting length compared with 91.9 ± 1.1% in control (P = 0.03). Importantly, calyculin A-treated cells did not exhibit an increase in myofilament Ca2+ sensitivity. In fact, there was no statistical difference, at any [Ca2+] tested, between the extent of shortening in the control cells and those preincubated with calyculin A. Although this technique is limited in its ability to measure myofilament Ca2+ sensitivity over the complete range of physiologically relevant Ca2+ concentrations, it is very effective in measuring Ca2+ sensitivity in the 100-500 nM range, where increases in Ca2+ sensitivity are very evident. Thus the results of these experiments reveal that the increase in contraction produced by calyculin A is not due to an increase in steady-state myofilament Ca2+ sensitivity.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of calyculin A, caffeine, and 8-bromo-cAMP on myofilament [Ca2+] sensitivity in chemically skinned mouse ventricular myocytes. Cells were skinned (10 µM digitonin) and then exposed to each [Ca2+] in succession from 1 to 500 nM. Cell length at each [Ca2+] was normalized to that at 1 nM [Ca2+]. Shown are plots of normalized cell length vs. [Ca2+] for control cells (n = 9), cells preincubated with 1 µM calyculin A (n = 10), cells in the presence of 5 mM caffeine (n = 3), and cells preincubated with 20 µM 8-bromo-cAMP and superfused with 1 µM 8-bromo-cAMP (n = 3).

It is possible that phosphatase inhibition could lead to targeted changes in one or more of the ionic currents that underlie the mouse ventricular action potential and thus produce the characteristic effects of calyculin A on the twitch. We began our analysis of this hypothesis by examining the effects of calyculin A on the action potential (Fig. 5A). Calyculin A prolonged the duration of the action potential, increasing the time to 50% repolarization from 3.6 ± 0.7 ms (n = 5) to 8.6 ± 1.0 ms (n = 5, P = 0.001) without having any effect on the resting potential (control: -73.5 ± 0.9 mV; calyculin A: -70.6 ± 1.6 mV, P = 0.19). These results suggest that electrophysiological actions of calyculin A are responsible for its characteristic effects on twitch magnitude and duration.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of preincubation in calyculin A on the mouse ventricular action potential and membrane K+ currents. A: representative action potentials from a control cell and a cell preincubated in 100 nM calyculin A. Each waveform is the average of 10 consecutive steady-state action potentials (1 Hz). B: average current-voltage relationships for inward rectifier K+ current (IK1) in control cells (n = 6) and cells preincubated with 1 µM calyculin A (n = 5). The holding potential was -70 mV, and currents were elicited by 300-ms test pulses between -120 and -40 mV. C: representative K+ current recordings from a control cell (left) and a cell preincubated with 1 µM calyculin A (right). Holding potential was -70 mV. Currents were elicited by 1,000-ms test pulses to potentials between -50 and +60 mV at 5-s intervals. Dashed line, zero current level. D: voltage dependence of the transient and sustained components of the mouse ventricular K+ current in control cells (n = 6) and cells preincubated with 1 µM calyculin A (n = 4). The amplitude of the transient component was the difference between the early peak of outward current and the current remaining at the end of the test pulse. The amplitude of the sustained component was the difference between the current remaining at the end of each test pulse and the holding current. E: average recovery from inactivation for the sustained component (top) and the transient component (bottom) of the mouse ventricular K+ current in control (n = 6) and in cells preincubated with 1 µM calyculin A (n = 7). The holding potential was -70 mV. Pairs of 200-ms voltage-clamp pulses to +50 mV were imposed, with interposed rest intervals ranging from 20 to 2,800 ms. There was an interval of 10 s between each pulse pair. The magnitude of each component of the current recorded from a test pulse (Itest) was normalized to that of the preceding conditioning pulse (I0), and the resulting values were plotted vs. the rest interval.

Calyculin A could increase the action potential duration by decreasing the activity of PP1 or PP2A involved in controlling the amplitude of repolarizing K+ currents. This was tested with whole cell voltage-clamp experiments on the inward rectifier K+ current (IK1), which is primarily responsible for determining the resting potential, and on the time- and voltage-dependent currents that underlie action potential repolarization. The effect of calyculin A on IK1 was examined by applying 300-ms test pulses to potentials between -120 and -40 mV from a holding potential of -70 mV. The magnitude of IK1 was calculated as the difference between the current at the end of the pulse and the holding current. The results are summarized in Fig. 5B, with average current-voltage relationships recorded from control cells (n = 6) and cells preincubated with calyculin A (n = 5). Figure 5B demonstrates that calyculin A is without effect on IK1.

Figure 5, C-E, summarizes the effects of calyculin A on the voltage- and time-dependent K+ currents that are responsible for action potential repolarization. In both control cells and in cells preincubated with calyculin A, the composite K+ currents exhibit a large and rapid outward transient, followed by decay to a maintained outward current (Fig. 5C). This is consistent with a recent study (14) from this laboratory and others (19, 51, 53), demonstrating that the composite mouse ventricular K+ current consists of contributions from at least three time- and voltage-dependent K+ currents, each with distinct activation and inactivation kinetics. Importantly, the average results presented in Fig. 5D indicate that calyculin A had no effect on the voltage dependence of either the transient or maintained components of the composite current. Because the contractile effects of calyculin A were manifest at a stimulation rate of 1 Hz (Fig. 3), it was also necessary to examine the recovery from inactivation of these currents. Recovery from inactivation was examined between 20 and 2,800 ms. Figure 5E shows that the time course of recovery of both the transient and sustained components of the current was unaffected by calyculin A. Thus the K+ currents that are important components of the mouse ventricular action potential are insensitive to calyculin A, revealing that localized phosphatase activity is not responsible for maintaining the steady-state amplitude of these currents.

Increased ICa could explain the effect of calyculin A on the action potential as well as directly account for the increased contraction magnitude. This possibility was examined under conditions in which ICa and cytosolic [Ca2+]i transients were recorded simultaneously. The Ca2+-sensitive fluorescent indicator indo 1 was included in the pipette filling solution, and [Ca2+]i was quantified using an in vitro calibration method (13). Figure 6A shows representative original records, and Fig. 6B shows the average voltage dependence of both ICa and the [Ca2+]i transient recorded from control cells and cells preincubated with calyculin A. The phosphatase inhibitor increased both ICa and the [Ca2+]i transient (P < 0.05) throughout the entire range of test potentials. For example, ICa is increased at 0 mV from 7.9 ± 0.6 pA/pF in control to 13.8 ± 0.8 pA/pF with calyculin A. Whereas the magnitude of ICa was markedly increased, the kinetics of ICa decay, examined between -14 and +28 mV, were unaffected by calyculin A. Currents recorded in both control and calyculin A exhibited biexponential decay, with a fast tau  of <10 ms and a slower component with a tau  between 30 and 50 ms. For example, the average fast tau  at 0 mV was 6.0 ± 0.4 ms (n = 6) in control and 6.5 ± 0.5 ms (n = 5) with calyculin A (P = 0.21). The respective slow tau  were 39.4 ± 3.4 and 37.0 ± 2.0 ms (P = 0.29).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of preincubation with calyculin A on L-type Ca2+ current (ICa) and the intracellular [Ca2+] ([Ca2+]i) transient in voltage-clamped mouse ventricular myocytes. A: simultaneously recorded families of [Ca2+]i transients (in µM, top) and ICa (in pA/pF, bottom) from a control cell (left) and a cell preincubated in 1 µM calyculin A (right). Cells were held at -70 mV between test pulses. Test pulses (-35 to +60 mV in 7-mV increments) were given from -40 mV after a 1-s voltage ramp from -70 mV. Repolarization was to -70 mV. To maintain sarcoplasmic reticulum Ca2+ loading in a steady state, three 200-ms conditioning pulses to 0 mV were imposed during the 13-s interval between each test pulse. Only the test pulse portions of the data are shown. B: voltage dependence of peak [Ca2+]i (top) and ICa (bottom) in control cells (n = 6) and cells preincubated with 1 µM calyculin A (n = 5). ICa density was calculated by subtracting the steady-state current at the end of each test pulse from the peak current at the beginning of the pulse and then normalizing to cell capacitance.

Like ICa, the [Ca2+]i transient was also markedly increased by calyculin A (Fig. 6). For example, the average peak [Ca2+]i at 0 mV was 827 ± 90 nM in control cells and 1,514 ± 185 nM in treated cells. Interestingly, however, the [Ca2+]i transients recorded from voltage-clamped cells preincubated with calyculin A exhibited accelerated decay with respect to control. The average tau  of decay of [Ca2+]i transients elicited during steady-state drives to 0 mV was 188 ± 17 ms (n = 4) in control cells and 128 ± 17 ms (n = 4) in cells preincubated in calyculin A (P = 0.02). These results demonstrate that calyculin A elicits a marked increase in ICa, which in turn produces an increase in the [Ca2+]i transient that activates contraction.

In a dynamic phosphorylation model, the functional effects of phosphatase inhibition are seen through the activity of a counteracting kinase. Thus phosphatase inhibition should be without effect once the kinase activity has been inhibited. Accordingly, the specificity of calyculin A was examined in combination experiments with the broad-spectrum serine-threonine kinase inhibitor staurosporine (46). As shown in Fig. 7B, staurosporine decreased steady-state ICa and, importantly, completely blocked the stimulatory action of calyculin A (Fig. 7B). The results of the reverse experiment were also consistent with this model, because staurosporine was completely without effect once the responses to calyculin A were fully developed (Fig. 7C). Thus the effects of calyculin A on ICa occur through phosphatase inhibition rather than through a nonspecific effect of this agent on Ca2+ channels.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of serial addition of calyculin A (Caly A) and staurosporine (Stau) on ICa. A: superimposed currents recorded during steps from -40 to -7 mV. The control current (Con) was recorded first, followed by the current recorded after 5 min in calyculin A and the current recorded after 5 min in calyculin A and staurosporine. Note the increase during calyculin A and the lack of effect of subsequent addition of staurosporine. B: superimposed currents in which staurosporine was added first, followed by exposure to calyculin A and staurosporine. Note the decreased magnitude in staurosporine and the lack of effect of subsequent addition of calyculin A. C: histogram summarizing the experiments described in A (left, n = 4) and B (right, n = 5).

These data demonstrate that the increase in the twitch contraction seen in Fig. 3 can be explained by an increase in ICa brought about specifically by the phosphatase inhibition produced by calyculin A. However, recall the effects of calyculin A described above on the kinetics of [Ca2+]i transient decay (Fig. 6) and twitch contraction (Fig. 3). When these are compared, there is an apparent discrepancy, with calyculin A accelerating the decay of the voltage-clamp-induced [Ca2+]i transient while it prolongs the duration of the field-stimulated twitch contraction.

To address this discrepancy, we measured [Ca2+]i transients and twitch contractions simultaneously in field-stimulated cells. This allowed us to examine the relationships among the magnitudes, durations, and kinetics of the [Ca2+]i transients and resulting twitch contractions. The measurements were made in fluo 3-AM-loaded cells using a laser scanning confocal microscope in the line-scan mode. A representative line-scan image and [Ca2+]i transient (F/F0) are shown in Fig. 8, and the results are summarized in Table 1. As in cells not loaded with fluorescent dye (Fig. 3), calyculin A markedly increased the magnitude and duration of the field-stimulated twitch contraction. Also, as expected from Fig. 6, calyculin A markedly increased the magnitude of the field-stimulated [Ca2+]i transient. However, despite the fact that the tau  of decay of the [Ca2+]i transient was accelerated by 25%, the duration of the [Ca2+]i transient, measured as the time to 50% decay (T50), was not significantly different from control. This suggests that calyculin A does not substantially stimulate SR Ca2+ uptake.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 8.   Simultaneous measurement of the [Ca2+]i transient [fluorescence intensity of each pixel (F)/average resting intensity (Fo)] and contraction and the effect of preincubation with calyculin A on the [Ca2+]i transient in fluo 3-loaded mouse ventricular myocytes. A: schematic of method for simultaneous measurement of [Ca2+]i and contraction from a confocal line-scan image. A single line on the long axis of the cell is scanned repeatedly at 2-ms intervals. A line-scan image is constructed with time represented horizontally and the position along the scan line represented vertically. During the scan, the cell is field stimulated, resulting in shortening and relengthening. This changes the portion of the image that exhibits fluorescence. The length of the cell during each line scan is determined by measuring the portion of the line that exhibits fluorescence. From that information, a plot of cell length (L) vs. time (t) is constructed. F/F0 is calculated by determining the fluorescence from the same small region of each line scan (F) and dividing by the fluorescence of the same region in the absence of stimulation (F0). From that information, a plot of F/F0 vs. time is constructed. B: representative line-scan image and the twitch contraction record (top) and [Ca2+]i transient (bottom) derived from that image. C: superimposed representative steady-state [Ca2+]i transients from a control cell and a cell preincubated with 100 nM calyculin A. D: same [Ca2+]i transients normalized between resting and peak F/F0 for each.


                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Effects of 100 nM calyculin A and 1 µM isoproterenol on [Ca2+]i transient and twitch contraction in single isolated mouse ventricular myocytes

To test the role of PP1/PP2A in regulating SR Ca2+ uptake, we compared the effects of calyculin A (125 nM) with those of the beta -adrenergic agonist isoproterenol (1 µM). beta -Adrenergic stimulation is known to greatly stimulate the activity of the SR Ca2+ pump. The magnitudes of both the [Ca2+]i transient and contraction were the same in isoproterenol as in calyculin A (Table 1). However, the effects of isoproterenol on the kinetics of the [Ca2+]i transient were quite distinct from those of calyculin A. Whereas calyculin A was without effect on the T50 of the [Ca2+]i transient, isoproterenol decreased this parameter by ~25%. Furthermore, isoproterenol decreased the tau  of [Ca2+]i decay by ~50%, essentially doubling the effect of calyculin A. Calyculin A and isoproterenol had identical effects on the action potential and ICa, and, importantly, isoproterenol was without effect on ICa after calyculin A (data not shown). Thus the differences between the effects of calyculin A and isoproterenol on the [Ca2+]i transient kinetics cannot be attributed to different effects on these factors. Taken together, these data suggest that any effects of PP1 or PP2A inhibition on the rate of SR Ca2+ uptake are minimal compared with the increase produced by beta -adrenergic stimulation. However, inhibition of one or both of these phosphatases results in a marked increase in ICa, which translates into a substantial increase in the magnitude and duration of contraction.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Phosphatase inhibition has been shown to have a wide variety of effects on cardiac cells. It can modify the responses to adenosine receptor stimulation (39), classic beta -adrenergic stimulation (26, 27), and beta 2-adrenergic stimulation (32). On its own, phosphatase inhibition has also been shown to mimic the cardioprotective effects of ischemic preconditioning (2, 3). With respect to the E-C coupling cascade, Ca2+ currents increase during phosphatase inhibition (20, 40, 41, 43, 50), and biochemical measurements have also indicated that myofilament proteins and phospholamban can become phosphorylated (4, 40, 41). Thus because most of the components of the E-C coupling cascade are known to be regulated in some fashion by phosphorylation, it was expected that nearly complete inhibition of the major serine-threonine phosphatase activity in cardiac cells would have a broad impact on all steps of this process. In particular, phosphatase inhibitors might mimic the action of signaling cascades that activate PKC or PKA. alpha -Adrenergic stimulation, acting through PKC, increases myofilament Ca2+ sensitivity (21), decreases time- and voltage-dependent K+ currents (1, 18), and produces a contractile effect similar to that seen here for calyculin A (18). beta -Adrenergic stimulation, acting through PKA, produces positive inotropic and lusitropic effects by increasing the magnitude of the Ca2+ current (8, 24), increasing SR Ca2+ uptake (31, 33), and decreasing myofilament Ca2+ sensitivity (21). Unexpectedly, however, the results here reveal that when the major phosphatases in the heart are broadly inhibited by calyculin A, the acute contractile effects cannot be explained by a global effect on the entire E-C coupling cascade. Rather, these new findings raise several questions central to the local steady-state control of E-C coupling by phosphatases in the heart.

Phosphatase inhibition and myofilament Ca2+ sensitivity. To examine potential increases in myofilament Ca2+ sensitivity, we utilized an unloaded permeabilized cell model. This method was very effective in measuring steady-state myofilament Ca2+ sensitivity over a concentration range in which such increases would be evident. Control experiments with caffeine validated this approach. Because no increases in myofilament Ca2+ sensitivity were observed with calyculin A at Ca2+ concentrations as high as 500 nM, it cannot account for the inhibitor-evoked increase in the magnitude and duration of contraction. A limitation of this unloaded cell approach is that cell shortening could not be assessed over the complete physiologically relevant Ca2+ concentration range. Thus it is not possible to exclude the possibility that phosphatase inhibition with calyculin A actually decreased myofilament Ca2+ sensitivity. It is also possible that phosphorylation-dependent changes in dynamic myofilament properties, such as the cross-bridge cycling rate (48), could occur that would not be detected in these steady-state measurements. However, taken together, these studies reveal that PP1/PP2A inhibition does not prolong the twitch duration through an increase in the steady-state Ca2+-dependent properties of the myofilaments.

Phosphatase inhibition and repolarizing K+ currents. The similarity between the effects of calyculin A and alpha -adrenergic agonists on contractility and action potential duration (18) suggested that the time- and voltage-dependent repolarizing K+ currents are regulated by PP1/PP2A inhibition. In fact, phosphatase inhibitors have been shown to decrease delayed rectifier K+ currents in the frog atrium (20). Furthermore, alpha 1-adrenergic agonists increase the magnitude and duration of contractions (18), prolong action potentials (1, 18), and reduce K+ currents in isolated rat ventricular myocytes (1, 18) through activation of PKC (1). The mouse ventricle exhibits a wide variety of time- and voltage-dependent K+ currents. There are two transient outward currents, termed Ito,f and Ito,s for their fast and slow inactivation kinetics, respectively (51). In addition, there is a rapidly activating, slowly inactivating current, termed IK,slow (14, 19, 51, 53), and a noninactivating current, termed IK,ss (14, 51). In addition, the mouse also possesses IK1, which is responsible for maintaining the resting potential but has also been shown to affect action potential duration (52). Precise pharmacological separation of these currents is difficult because there are no specific blockers that allow observation of each component in isolation. Kinetic separation of these currents requires the use of very long voltage-clamp pulses. In a recent study (14), we demonstrated that agents that affect any individual K+ current will also affect the composite K+ current, which can be separated into a transient and a maintained component. In the present study, we report that calyculin A was completely without effect on either the transient or maintained component of the current (Fig. 5D). Furthermore, there was no effect on the recovery from inactivation of either component over the range of 20 ms to nearly 3 s. Thus inhibition of PP1/PP2A has no effect on these K+ currents and cannot explain the increase in contractility that we observe (Fig. 3). It is interesting to note that calcineurin, the calcium/calmodulin-dependent phosphatase, does not regulate cardiac K+ currents either (12, 14). Thus ventricular K+ currents, in contrast to ICa, are not locally regulated by any of the major serine-threonine phosphatases.

Phosphatase inhibition and ICa. Of the targets studied in this report, the L-type Ca2+ channel proved to be the most sensitive to PP1/PP2A inhibition. This might have been expected because phosphatase inhibitors increase ICa in both frog atrial and guinea pig ventricular myocytes (20, 23, 27, 28, 40, 41). Furthermore, okadaic acid increases ICa in isolated single channels (43, 50), underscoring the role of local PP1 and perhaps PP2A in dynamic control of L-type Ca2+ channel activity. In this regard, a recent biochemical study (10) demonstrated that PP2A binds directly to the alpha -subunit of the cardiac L-type Ca2+ channel. Taken together, these data demonstrate that in intact cells the L-type Ca2+ channel is very sensitive to serine-threonine phosphatase activity in the absence of humoral stimulation. It is also clear that the L-type Ca2+ channel is equally sensitive to serine-threonine kinase activity, as demonstrated by the fact that the broad-spectrum kinase inhibitor staurosporine decreased ICa and prevented the stimulatory action of calyculin A. It will be important to identify the underlying kinases that oppose the phosphatase action and regulate ICa under these conditions.

Phosphatase inhibition and SR Ca2+ uptake. During the course of these studies, analysis of the action of calyculin A revealed conflicting results regarding SR Ca2+ uptake. In particular, phosphatase inhibition accelerated the decay of the voltage-clamp-induced [Ca2+]i transient, whereas it markedly prolonged the duration of the field-stimulated twitch contraction. This apparent discrepancy raised uncertainty about the role of serine-threonine phosphatases in regulating SR Ca2+ pump activity in the absence of humoral stimulation. It is important to note that the tau  of [Ca2+]i decay decreases as the magnitude of the [Ca2+]i transient increases (5). Because calyculin A markedly increases peak [Ca2+]i, the concomitant increase in the decay rate of the [Ca+]i transient does not prove that SR Ca2+ uptake is activated.

To critically evaluate this apparent discrepancy, we compared the effects of calyculin A and the beta -adrenergic agonist isoproterenol on [Ca2+]i transients and contractions in field-stimulated cells. beta -Adrenergic stimulation is known to greatly stimulate the activity of the SR Ca2+ pump (34, 47). Several lines of experimental evidence indicated that phosphatase inhibition alone did not substantially increase SR Ca2+ pump activity. First, calyculin A did not change the T50 of the [Ca2+]i transient, whereas isoproterenol decreased it by 25% (Fig. 8 and Table 1). Second, isoproterenol had a much greater effect on the tau  of [Ca2+]i decay than did calyculin A (Table 1). Because peak [Ca2+]i was the same with both calyculin A and isoproterenol (Table 1), this difference reflects a real difference in the rates of SR Ca2+ pump activity (5). These functional results are consistent with the recent biochemical observation that cantharidin, another PP1/PP2A inhibitor, does not increase the phosphorylation state of the PKA site, Ser16, on phospholamban in the guinea pig ventricle (7). We conclude from our measurements of [Ca2+]i decay that calyculin A produces no stimulation of the mouse ventricular SR Ca2+-ATPase. Thus the prolongation of contraction results from the fact that [Ca2+]i remains in the range that fully activates myofilaments for a longer period of time and, even though the T50 of the [Ca2+]i transient is the same as that of the control, the [Ca2+]i at T50 is substantially higher.

In summary, the use of a rapid and potent PP1/PP2A inhibitor has provided insight into the range of action of this important family of phosphatases in controlling the E-C coupling cascade in cardiac myocytes in the absence of neural or humoral stimulation. Precise functional analyses here reveal that, rather than controlling many steps in the cascade, these signaling enzymes have a major role principally in the regulation of steady-state L-type Ca2+ channel activity. It will be important to know if such a dynamic balance of phosphorylation is altered under conditions of heart failure.


    ACKNOWLEDGEMENTS

This work was supported in part by National Institutes of Health Grants PO1 HL-27867, AG-1463 (to T. B. Rogers), and HL-36874 (to W. J. Lederer), and in part by a GIA grant from the American Heart Association, Maryland Affiliate (to X. Long).


    FOOTNOTES

* W. H. duBell and M. S. Gigena contributed equally to the data presented in this work.

Address for reprint requests and other correspondence: T. B. Rogers, Dept. of Biochemistry and Molecular Biology, Univ. of Maryland, 108 N. Greene St., Baltimore, MD 21201 (E-mail: trogers{at}som.umaryland.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published September 27, 2001; 10.1152/ajpheart.00536.2001

Received 25 June 2001; accepted in final form 20 September 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Apkon, M, and Nerbonne JM. alpha 1-Adrenergic agonists selectively suppress voltage-dependent K+ currents in rat ventricular myocytes. Proc Natl Acad Sci USA 85: 8756-8760, 1988.

2.   Armstrong, SC, Gao W, Lane JR, and Ganote CE. Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia. J Mol Cell Cardiol 30: 61-73, 1998.

3.   Armstrong, SC, Hoover DB, Delacey MH, and Ganote CE. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J Mol Cell Cardiol 28: 1479-1492, 1996.

4.   Berrebi-Bertrand, I, Brument-Larignon N, Camelin JC, Quiniou MJ, and Bril A. Relationship between biochemical and functional effects of protein phosphatase 1 inhibitors in rabbit cardiac skinned fibers. J Mol Cell Cardiol 30: 1945-1954, 1998.

5.   Bers, DM, and Berlin JR. Kinetics of [Ca]i decline in cardiac myocytes depend on peak [Ca]i. Am J Physiol Cell Physiol 268: C271-C277, 1995.

6.   Bialojan, C, and Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256: 283-290, 1998.

7.   Boknik, P, Khorchidi S, Bodor GS, Huke S, Knapp J, Linck B, Luss H, Muller FU, Schmitz W, and Neumann J. Role of protein phosphatases in regulation of cardiac inotropy and relaxation. Am J Physiol Heart Circ Physiol 280: H786-H794, 2001.

8.   Brum, G, Osterrieder W, and Trautwein W. beta -Adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp. Pflügers Arch 401: 111-118, 1984.

9.   Cohen, P, Alemany S, Hemmings BA, Resink TJ, Stralfors P, and Lim Tung HY. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle. Methods Enzymol 159: 390-408, 1988.

10.   Davare, MA, Horne MC, and Hell JW. Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase. J Biol Chem 275: 39710-39717, 2000.

11.   Dell'Acqua, ML, and Scott JD. Protein kinase A anchoring. J Biol Chem 272: 12881-12884, 1997.

12.   DuBell, WH, Gaa ST, Lederer WJ, and Rogers TB. Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. Am J Physiol Heart Circ Physiol 275: H2041-H2052, 1998.

13.   DuBell, WH, Lederer WJ, and Rogers TB. Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes. J Physiol (Lond) 493: 793-800, 1996.

14.   DuBell, WH, Lederer WJ, and Rogers TB. K+ currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. Am J Physiol Heart Circ Physiol 278: H886-H897, 2000.

15.   Eisner, DA, and Valdeolmillos M. The mechanism of the increase of tonic tension produced by caffeine in sheep cardiac Purkinje fibres. J Physiol (Lond) 364: 313-326, 1985.

16.   Fabiato, A, and Fabiato F. Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells. J Physiol (Paris) 75: 463-505, 1979.

17.   Favre, B, Turowski P, and Hemmings BA. Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid and tautomycin. J Biol Chem 272: 13856-13863, 1997.

18.   Fedida, D, and Bouchard RA. Mechanism for the positive inotropic effect of alpha 1-adrenoceptor stimulation in rat cardiac myocytes. Circ Res 71: 673-688, 1992.

19.   Fiset, C, Clark RB, Larsen TS, and Giles WR. A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J Physiol (Lond) 505: 557-563, 1997.

20.   Frace, AM, and Hartzell HC. Opposite effects of phosphatase inhibitors on L-type calcium and delayed rectifier currents in frog cardiac myocytes. J Physiol (Lond) 472: 305-326, 1993.

21.   Gambassi, G, Spurgeon HA, Lakatta EG, Blank PS, and Capogrossi MC. Different effects of alpha  and beta -adrenergic stimulation on cytosolic pH and myofilament responsivness to Ca2+ in cardiac myocytes. Circ Res 71: 870-882, 1992.

22.   Gao, T, Yatani A, Dell'Acqua ML, Sako H, Green SA, Dascal N, Scott JD, and Hosey MM. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19: 185-196, 1997.

23.   Hartzell, HC, Hirayama Y, and Petit-Jacques J. Effects of protein phosphatase and kinase inhibitors on the cardiac L-type Ca current suggest two sites are phosphorylated by protein kinase A and another protein kinase. J Gen Physiol 106: 393-414, 1995.

24.   Haworth, RA, Griffin P, Saleh B, Goknur AB, and Berkoff HA. Contractile function of isolated young and adult rat heart cells. Am J Physiol Heart Circ Physiol 253: H1484-H1491, 1987.

25.   Herzig, JE, Köhler G, Pfitzer G, Rüegg JC, and Wölffle G. Cyclic AMP inhibits contractility of detergent treated glycerol-extracted cardiac muscle. Pflügers Arch 391: 208-212, 1981.

26.   Hescheler, J, Kameyama M, Trautwein W, Mieskes G, and Soling HD. Regulation of the cardiac calcium channel by protein phosphatases. Eur J Biochem 165: 261-266, 1987.

27.   Hescheler, J, Mieskes G, Ruegg JC, Takai A, and Trautwein W. Effects of a protein phosphatase inhibitor, okadaic acid, on membrane currents of isolated guinea-pig cardiac myocytes. Pflügers Arch 412: 248-252, 1988.

28.   Hirayama, Y, and Hartzell HC. Effects of protein phosphatase and kinase inhibitors on Ca2+ and Cl- currents in guinea pig ventricular myocytes. Mol Pharmacol 52: 725-734, 1997.

29.   Huang, X, Pi Y, Lee KJ, Henkel AS, Gregg RG, Powers PA, and Walker JW. Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. Circ Res 84: 1-8, 1999.

30.   Ishihara, H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, and Uemura D. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 159: 871-877, 1989.

31.   James, P, Inui M, Tada M, Chiesi M, and Carafoli E. Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature 342: 90-92, 1989.

32.   Kuschel, M, Zhou YY, Cheng H, Zhang SJ, Chen Y, Lakatta EG, and Xiao RP. Gi protein-mediated functional compartmentalization of cardiac beta 2-adrenergic signaling. J Biol Chem 274: 22048-22052, 1999.

33.   Lindemann, JP, Jones LR, Hathaway DR, Henry BG, and Watanabe AM. beta -Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles. J Biol Chem 258: 464-471, 1983.

34.   MacDougall, LK, Jones LR, and Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem 196: 725-734, 1991.

35.   Marks, AR. Cardiac intracellular calcium release channels. Circ Res 87: 8-11, 2000.

36.   Marx, SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, and Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376, 2000.

37.   Mochly-Rosen, D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J, and Dorn GW II. Cardiotrophic effects of protein kinase Cepsilon : analysis by in vivo modulation of PKCepsilon translocation. Circ Res 86: 1173-1179, 2000.

38.   Mumby, MC, Russell KL, Garrad LJ, and Green DD. Cardiac contractile protein phosphatases: purification of two enzyme forms and their characterization with subunit-specific antibodies. J Biol Chem 262: 6257-6265, 1987.

39.   Narayan, P, Mentzer RM, and Lasley RD. Phosphatase inhibitor cantharidin blockes adenosine A1 receptor antiadrenergic effect in rat cardiac myocytes. Am J Physiol Heart Circ Physiol 278: H1-H7, 2000.

40.   Neumann, J, Boknik P, Herzig S, Schmitz W, Scholz H, Gupta RC, and Watanabe AM. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am J Physiol Heart Circ Physiol 265: H257-H266, 1993.

41.   Neumann, J, Boknik P, Herzig S, Schmitz W, Scholz H, Wiechen K, and Zimmerman N. Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor. J Pharmacol Exp Ther 271: 535-541, 1994.

42.   Okazaki, O, Suda N, Hongo K, Konishi M, and Kurihara S. Modulation of Ca2+ transients and contractile properties by beta -adrenoceptor stimulation in ferret ventricular myocytes. J Physiol (Lond) 423: 221-240, 1990.

43.   Ono, K, and Fozzard HA. Two phosphatase sites on the Ca2+ channel affecting different kinetic functions. J Physiol (Lond) 470: 73-84, 1993.

44.   Pinna, LA, and Donella-Deana A. Phosphorylated synthetic peptides as tools for studying protein phosphatases. Biochim Biophys Acta 1222: 415-431, 1994.

45.   Rodriguez, MM, Ron D, Ron D, Chen CH, and Mochly-Rosen D. RACK1, a protein kinase C anchoring protein, coordinates the binding of activated protein kinase C and select pleckstrin homology domains in vitro. Biochemistry 38: 13787-13794, 1999.

46.   Ruegg, UT, and Burgess GM. Staurosporin, K-252, and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 10: 18-22, 1989.

47.   Steenaart, NAE, Ganim JR, DiSalvo J, and Kranias EG. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch Biochem Biophys 293: 17-24, 1992.

48.   Weisberg, A, and Weiser R. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc Natl Acad Sci USA 93: 8999-9003, 1996.

49.   Wendt, IR, and Stephensen DG. Effects of caffeine on Ca-activated force production in skinned cardiac and skeletal muscle fibres of the rat. Pflügers Arch 398: 210-216, 1983.

50.   Wiechen, K, Yue DT, and Herzig S. Two distinct functional effects of protein phosphatase inhibitors on guinea-pig cardiac L-type Ca2+ channels. J Physiol (Lond) 484: 583-592, 1995.

51.   Xu, H, Guo W, and Nerbonne JM. Four kinetically distinct depolarization-activated K+ currents in adult mouse ventricular myocytes. J Gen Physiol 113: 661-677, 1999.

52.   Zaritsky, JJ, Redell JB, Tempel BL, and Schwarz TL. The consequences of disrupting cardiac inwardly rectifying K+ current (IK1) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol (Lond) 533: 697-710, 2001.

53.   Zhou, J, Jeron A, London B, Han X, and Koren G. Characterization of a slowly inactivating outward current in adult mouse ventricular myocytes. Circ Res 83: 806-814, 1998.


Am J Physiol Heart Circ Physiol 282(1):H38-H48
0363-6135/02 $5.00 Copyright © 2002 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Tsujikawa, Y. Song, M. Watanabe, H. Masumiya, S. A. Gupte, R. Ochi, and T. Okada
Cholesterol depletion modulates basal L-type Ca2+ current and abolishes its -adrenergic enhancement in ventricular myocytes
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H285 - H292.
[Abstract]